Xencor Inc.

05/26/2022 | Press release | Distributed by Public on 05/27/2022 01:01

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors